Getting to the Heart of the Matter... Results from a Regional Survey of Hospice Providers Regarding the Care of Patients with Advanced Heart Failure

Holder RM, Walker K, Ruiz G, Panke JT, Kelemen AM, Groninger H

BACKGROUND

Frederick

Heart failure (HF)

- Leading cause of hospitalizations
- High symptom burden
- Poor disease state education
- Prognostication at all stages difficult
 - 20% of Stage D survival at 5 years
 - 1/3 HF deaths are sudden
 - 36% of patients die 1 year after hospital admission for HF
 - Advanced therapies reduce mortality
 - Implantable cardiac defibrillator
 - IV inotrope therapy
 - Left-ventricular assist device

MedStar Washington Hospital Center (MWHC)

- •926-bed tertiary care facility in metropolitan Washington, DC
- •Serves greater area of DC, MD, and VA, including rural counties
- MedStar Heart and Vascular Institute provides supportive and interventional care for patients with advanced HF

OBJECTIVE


To determine knowledge and attitudes of hospice providers regarding the perceived need of HF patients at the end of life


METHODS

In May 2015, MWHC invited regional hospice stakeholders to a summit to discuss hospice care of patients with advanced HF

- Attendees were asked to complete a survey
- •Those unable to attend completed an electronic survey
- Survey tool
 - 17-items
 - Respondent demographics
 - HF patient case mix and care providers
 - Barriers to care of HF patients
 - Timeliness of referrals

RESULTS





Willingness to accept patients with advanced heart failure therapies based on hospice experience. Percent Inotropes LVADs

11 to 15

Years of experience


Parenteral Analgesics

16 to 20

>20

6 to 10

If the cost of providing



DISCUSSION AND CONCLUSIONS

- Hospice care for patients with advanced heart failure can be difficult to coordinate based on poor prognostication and utilization of advanced, life-prolonging therapies.
- Two-thirds of hospice providers will accept patients with inotropes and LVADs; experience and cost are barriers.
- Most hospice providers would pay for palliative inotropes if the cost was comparable to parenteral opioid infusions.
- Opportunities exist to partner with and educate local hospice organizations on advanced heart failure therapies.

Contact

MedStar Washington Hospital Center Section of Palliative Care Email: hunter.groninger@medstar.net Website: www.medstarwashington.org Phone: (202) 877-7445



MedStar Washington Hospital Center

References

- Curtis LF, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med. 8;168(22):2481-8.
- Unroe KT, et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med. 14;171(3):196-203.
- Chen-Scarabelli C, et al. Dilemmas in end-stage heart failure. J Geriatr Cardiol. 12(1):57-65.
- Stewart S, et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 3(3):315-22.